sorafenib has been researched along with alpha-aminopyridine in 7 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (alpha-aminopyridine) | Trials (alpha-aminopyridine) | Recent Studies (post-2010) (alpha-aminopyridine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 5,813 | 460 | 3,246 |
| Protein | Taxonomy | sorafenib (IC50) | alpha-aminopyridine (IC50) |
|---|---|---|---|
| Botulinum neurotoxin type A | Clostridium botulinum | 1.8 | |
| Nitric oxide synthase, endothelial | Homo sapiens (human) | 2.8 | |
| Nitric oxide synthase, brain | Homo sapiens (human) | 6 | |
| Nitric oxide synthase, brain | Rattus norvegicus (Norway rat) | 9 | |
| Nitric oxide synthase, inducible | Homo sapiens (human) | 1.9 | |
| Phosphatidylinositol 4-kinase alpha | Homo sapiens (human) | 7.1 | |
| Phosphatidylinositol 4-kinase type 2-beta | Homo sapiens (human) | 7.1 | |
| Phosphatidylinositol 4-kinase type 2-alpha | Homo sapiens (human) | 7.1 | |
| Phosphatidylinositol 4-kinase beta | Homo sapiens (human) | 7.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| de Gramont, A; Dos Santos, C; Faivre, S; Raymond, E; Riveiro, ME; Serova, M; Slimane, K; Tijeras-Raballand, A | 1 |
| Fan, L; Han, TT; Li, JY; Xu, W | 1 |
| Galanis, A; Levis, M | 1 |
| Dou, H; Feng, K; Jiang, X; Li, Z; Wang, T; Zhang, Y; Zhou, F | 1 |
| Eriksson, LA; Gao, C; Grøtli, M | 1 |
| De Toni, EN; Denk, G; Gerbes, AL; Hohenester, S; Itzel, T; Mayerle, J; Munker, S; Ofner, A; Reiter, FP; Schiergens, TS; Spampatti, M; Teufel, A; Wimmer, R; Ye, L; Ziesch, A | 1 |
| Hu, X; Jian, C; Li, D; Li, P; Li, Y; Li, Z; Yi, W; Yu, A; Yuan, Y; Zhao, Y | 1 |
1 review(s) available for sorafenib and alpha-aminopyridine
| Article | Year |
|---|---|
Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.
Topics: Aminopyridines; Antineoplastic Agents; Benzylamines; Chemokine CXCL12; Clinical Trials as Topic; Cyclams; Dasatinib; Heterocyclic Compounds; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Morpholines; Niacinamide; Oxazines; Phenylurea Compounds; Protein Kinase Inhibitors; Purines; Pyridines; Pyrimidines; Quinazolinones; Receptors, CXCR4; Sorafenib; Thalidomide; Thiazoles; Tumor Microenvironment | 2014 |
6 other study(ies) available for sorafenib and alpha-aminopyridine
| Article | Year |
|---|---|
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Topics: Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Everolimus; Humans; Imidazoles; Indoles; Kidney Neoplasms; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2013 |
Inhibition of c-Kit by tyrosine kinase inhibitors.
Topics: Aminopyridines; Antineoplastic Agents; Benzothiazoles; Biomarkers; Bone Marrow; Cell Line, Tumor; Clinical Trials as Topic; Dasatinib; fms-Like Tyrosine Kinase 3; Gene Expression; Hair; Hematopoietic Stem Cells; Humans; Indazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pigmentation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Thiazoles | 2015 |
Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoxazoles; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Real-Time Polymerase Chain Reaction; Sorafenib; Transfection; Xenograft Model Antitumor Assays | 2015 |
Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase.
Topics: Aminopyridines; Binding Sites; Humans; Indoles; Kinetics; Molecular Docking Simulation; Molecular Dynamics Simulation; Naphthalenes; Niacinamide; Oligonucleotides; Phenylurea Compounds; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrazoles; Sorafenib; Structural Homology, Protein; Thermodynamics; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p16; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; Hepatocytes; Humans; Liver Neoplasms; Purines; Retinoblastoma Protein; RNA, Small Interfering; Sorafenib | 2019 |
Chidamide augment sorafenib-derived anti-tumor activities in human osteosarcoma cells lines and xenograft mouse model.
Topics: Aminopyridines; Animals; Benzamides; Bone Neoplasms; Cell Line, Tumor; Heterografts; Histone Deacetylase Inhibitors; Humans; Mice; Osteosarcoma; Sorafenib | 2022 |